{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T19:24:45Z","timestamp":1789068285890,"version":"build-2803163510"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:00:00Z","timestamp":1614211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST106-2320-B-037-003-MY3"],"award-info":[{"award-number":["MOST106-2320-B-037-003-MY3"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004694","name":"Kaohsiung Medical University","doi-asserted-by":"publisher","award":["KMU-TP105H03"],"award-info":[{"award-number":["KMU-TP105H03"]}],"id":[{"id":"10.13039\/501100004694","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Inflammation in the tumor microenvironment is positively correlated with cancer progression and metastasis as well as the risk of thromboembolism in lung cancer patients. Here we show, in human non-small cell lung cancer (NSCLC) cell lines, the master inflammatory cytokine tumor necrosis factor (TNF-\u03b1) induced tissue factor expression and procoagulant activity, and these effects were potently inhibited by 4\u03b2-hydroxywithanolide E (4HW), a natural compound isolated from\n                    <jats:italic>Physalis peruviana<\/jats:italic>\n                    . Furthermore, combination of 4HW and TNF-\u03b1 caused synergistic cytotoxicity against NSCLC cells by inducing caspase-dependent apoptosis. The underlying mechanism by which 4HW reverses the procoagulant effect of TNF-\u03b1 but enhances its cytotoxic effect appears to be due to inhibition of NF-\u03baB, which is a key switch for both inflammation-induced coagulation and cell survival. Our results suggest that 4HW may have a potential application for treating inflammation-derived cancer progression and cancer-associated hypercoagulable state.\n                  <\/jats:p>","DOI":"10.1038\/s41598-021-84207-8","type":"journal-article","created":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T06:04:11Z","timestamp":1614233051000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Golden berry 4\u03b2-hydroxywithanolide E prevents tumor necrosis factor \u03b1-induced procoagulant activity with enhanced cytotoxicity against human lung cancer cells"],"prefix":"10.1038","volume":"11","author":[{"given":"Kan-Yen","family":"Hsieh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju-Ying","family":"Tsai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Han","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Rong","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui-Chun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chin-Chung","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,25]]},"reference":[{"key":"84207_CR1","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1097\/JTO.0000000000000551","volume":"10","author":"DP Carbone","year":"2015","unstructured":"Carbone, D. P., Gandara, D. R., Antonia, S. J., Zielinski, C. & Paz-Ares, L. Non-small-cell lung cancer: Role of the immune system and potential for immunotherapy. J. Thorac. Oncol. 10, 974\u2013984 (2015).","journal-title":"J. Thorac. Oncol."},{"key":"84207_CR2","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/S0140-6736(00)04046-0","volume":"357","author":"F Balkwill","year":"2001","unstructured":"Balkwill, F. & Mantovani, A. Inflammation and cancer: Back to virchow?. Lancet 357, 539\u2013545 (2001).","journal-title":"Lancet"},{"key":"84207_CR3","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12967-018-1611-7","volume":"16","author":"SF Josephs","year":"2018","unstructured":"Josephs, S. F. et al. Unleashing endogenous TNF-\u03b1 as a cancer immunotherapeutic. J. Transl. Med. 16, 242 (2018).","journal-title":"J. Transl. Med."},{"key":"84207_CR4","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 9, 361\u2013371 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"84207_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/sj.bjc.6605530","volume":"102","author":"Y Wu","year":"2010","unstructured":"Wu, Y. & Zhou, B. P. TNF-\u03b1\/NF-\u03baB\/Snail pathway in cancer cell migration and invasion. Br. J. Cancer 102, 639\u2013644 (2010).","journal-title":"Br. J. Cancer"},{"key":"84207_CR6","doi-asserted-by":"publisher","first-page":"5094","DOI":"10.2741\/3066","volume":"13","author":"G Sethi","year":"2008","unstructured":"Sethi, G., Sung, B. & Aggarwal, B. B. TNF: A master switch for inflammation to cancer. Front. Biosci. 13, 5094\u20135107 (2008).","journal-title":"Front. Biosci."},{"key":"84207_CR7","doi-asserted-by":"publisher","first-page":"2774","DOI":"10.2741\/2884","volume":"13","author":"S Mocellin","year":"2008","unstructured":"Mocellin, S. & Nitti, D. TNF and cancer: The two sides of the coin. Front. Biosci. 13, 2774\u20132783 (2008).","journal-title":"Front. Biosci."},{"key":"84207_CR8","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1007\/s00423-003-0416-0","volume":"388","author":"R Li","year":"2003","unstructured":"Li, R., Ruttinger, D., Li, R., Si, L. S. & Wang, Y. L. Analysis of the immunological microenvironment at the tumor site in patients with non-small cell lung cancer. Langenbecks Arch. Surg. 388, 406\u2013412 (2003).","journal-title":"Langenbecks Arch. Surg."},{"key":"84207_CR9","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1093\/jnci\/djm083","volume":"99","author":"M Seike","year":"2007","unstructured":"Seike, M. et al. Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J. Natl. Cancer Inst. 99, 1257\u20131269 (2007).","journal-title":"J. Natl. Cancer Inst."},{"key":"84207_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1046\/j.1365-3083.2003.01205.x","volume":"57","author":"D Matanic","year":"2003","unstructured":"Matanic, D. et al. Cytokines in patients with lung cancer. Scand. J. Immunol. 57, 173\u2013178 (2003).","journal-title":"Scand. J. Immunol."},{"key":"84207_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13045-014-0054-8","volume":"7","author":"X Han","year":"2014","unstructured":"Han, X., Guo, B., Li, Y. & Zhu, B. Tissue factor in tumor microenvironment: A systematic review. J Hematol. Oncol. 7, 54 (2014).","journal-title":"J Hematol. Oncol."},{"key":"84207_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.lungcan.2014.02.009","volume":"84","author":"M Alexander","year":"2014","unstructured":"Alexander, M. et al. Thromboembolism in lung cancer: An area of urgent unmet need. Lung Cancer 84, 275\u2013280 (2014).","journal-title":"Lung Cancer"},{"key":"84207_CR13","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jama.293.6.715","volume":"293","author":"JW Blom","year":"2005","unstructured":"Blom, J. W., Doggen, C. J., Osanto, S. & Rosendaal, F. R. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 293, 715\u2013722 (2005).","journal-title":"JAMA"},{"key":"84207_CR14","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1177\/0003319715614945","volume":"67","author":"E Salla","year":"2016","unstructured":"Salla, E. et al. Venous thromboembolism in patients diagnosed with lung cancer. Angiology 67, 709\u2013724 (2016).","journal-title":"Angiology"},{"key":"84207_CR15","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1016\/j.thromres.2012.10.014","volume":"131","author":"TH Toledano","year":"2013","unstructured":"Toledano, T. H., Kondal, D., Kahn, S. R. & Tagalakis, V. The occurrence of venous thromboembolism in cancer patients following major surgery. Thromb. Res. 131, e1-5 (2013).","journal-title":"Thromb. Res."},{"key":"84207_CR16","first-page":"585","volume":"24","author":"M Zhu","year":"2019","unstructured":"Zhu, M. et al. Correlations of coagulation indexes and inflammatory changes with the prognosis of lung cancer complicated with thromboembolic disease. J. BUON 24, 585\u2013590 (2019).","journal-title":"J. BUON"},{"key":"84207_CR17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.14740\/wjon1076w","volume":"8","author":"M Tomita","year":"2017","unstructured":"Tomita, M., Ayabe, T., Maeda, R. & Nakamura, K. Combination of advanced lung cancer inflammation index and C-reactive protein is a prognostic factor in patients with operable non-small cell lung cancer. World J. Oncol. 8, 175\u2013179 (2017).","journal-title":"World J. Oncol."},{"key":"84207_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/S0305-7372(02)00044-0","volume":"28","author":"AY Lee","year":"2002","unstructured":"Lee, A. Y. Cancer and thromboembolic disease: Pathogenic mechanisms. Cancer Treat. Rev. 28, 137\u2013140 (2002).","journal-title":"Cancer Treat. Rev."},{"key":"84207_CR19","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1160\/TH16-08-0615","volume":"117","author":"C Ay","year":"2017","unstructured":"Ay, C., Pabinger, I. & Cohen, A. T. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb. Haemost. 117, 219\u2013230 (2017).","journal-title":"Thromb. Haemost."},{"key":"84207_CR20","first-page":"123","volume":"20","author":"P Goldin-Lang","year":"2008","unstructured":"Goldin-Lang, P. et al. Tissue factor expression pattern in human non-small cell lung cancer tissues indicate increased blood thrombogenicity and tumor metastasis. Oncol. Rep. 20, 123\u2013128 (2008).","journal-title":"Oncol. Rep."},{"key":"84207_CR21","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.thromres.2019.07.007","volume":"181","author":"M Barbarawi","year":"2019","unstructured":"Barbarawi, M. et al. The role of anticoagulation in venous thromboembolism primary prophylaxis in patients with malignancy: A systematic review and meta-analysis of randomized controlled trials. Thromb. Res. 181, 36\u201345 (2019).","journal-title":"Thromb. Res."},{"key":"84207_CR22","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1200\/JCO.2015.64.0268","volume":"34","author":"F Macbeth","year":"2016","unstructured":"Macbeth, F. et al. Randomized phase III trial of standard therapy plus low molecular weight heparin in patients with lung cancer: Fragmatic trial. J. Clin. Oncol. 34, 488\u2013494 (2016).","journal-title":"J. Clin. Oncol."},{"key":"84207_CR23","first-page":"967","volume":"85","author":"G Grignani","year":"2000","unstructured":"Grignani, G. & Maiolo, A. Cytokines and hemostasis. Haematologica 85, 967\u2013972 (2000).","journal-title":"Haematologica"},{"key":"84207_CR24","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/j.phymed.2018.09.017","volume":"53","author":"HC Wang","year":"2019","unstructured":"Wang, H. C. et al. Different effects of 4\u03b2-hydroxywithanolide E and withaferin A, two withanolides from solanaceae plants, on the Akt signaling pathway in human breast cancer cells. Phytomedicine 53, 213\u2013222 (2019).","journal-title":"Phytomedicine"},{"key":"84207_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1002\/tox.22516","volume":"33","author":"JY Tang","year":"2018","unstructured":"Tang, J. Y. et al. 4\u03b2-hydroxywithanolide E selectively induces oxidative DNA damage for selective killing of oral cancer cells. Environ. Toxicol. 33, 295\u2013304 (2018).","journal-title":"Environ. Toxicol."},{"key":"84207_CR26","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1021\/acs.jnatprod.6b01129","volume":"80","author":"YM Xu","year":"2017","unstructured":"Xu, Y. M. et al. Withanolides from aeroponically grown Physalis peruviana and their selective cytotoxicity to prostate cancer and renal carcinoma cells. J. Nat. Prod. 80, 1981\u20131991 (2017).","journal-title":"J. Nat. Prod."},{"key":"84207_CR27","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/s10637-013-9987-y","volume":"32","author":"M Gu","year":"2014","unstructured":"Gu, M. et al. Structure-activity relationship (SAR) of withanolides to inhibit Hsp90 for its activity in pancreatic cancer cells. Invest. New Drugs 32, 68\u201374 (2014).","journal-title":"Invest. New Drugs"},{"key":"84207_CR28","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/1471-2407-10-46","volume":"10","author":"CY Yen","year":"2010","unstructured":"Yen, C. Y. et al. 4\u03b2-hydroxywithanolide E from Physalis peruviana (golden berry) inhibits growth of human lung cancer cells through DNA damage, apoptosis and G2\/M arrest. BMC Cancer 10, 46 (2010).","journal-title":"BMC Cancer"},{"key":"84207_CR29","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/molecules24061146","volume":"24","author":"ZN Ye","year":"2019","unstructured":"Ye, Z. N. et al. Physalis peruviana-derived 4\u03b2-hydroxywithanolide E, a novel antagonist of Wnt signaling, inhibits colorectal cancer in vitro and in vivo. Molecules 24, 1146 (2019).","journal-title":"Molecules"},{"key":"84207_CR30","doi-asserted-by":"publisher","first-page":"7290","DOI":"10.1038\/s41598-017-07472-6","volume":"7","author":"CC Lee","year":"2017","unstructured":"Lee, C. C. et al. 4\u03b2-hydroxywithanolide E modulates alternative splicing of apoptotic genes in human hepatocellular carcinoma Huh-7 cells. Sci. Rep. 7, 7290 (2017).","journal-title":"Sci. Rep."},{"key":"84207_CR31","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1021\/acs.jnatprod.8b00861","volume":"82","author":"EJ Park","year":"2019","unstructured":"Park, E. J., Sang-Ngern, M., Chang, L. C. & Pezzuto, J. M. Physalactone and 4\u03b2-hydroxywithanolide E isolated from Physalis peruviana inhibit LPS-induced expression of COX-2 and iNOS accompanied by abatement of Akt and STAT1. J. Nat. Prod. 82, 492\u2013499 (2019).","journal-title":"J. Nat. Prod."},{"key":"84207_CR32","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1016\/j.bmcl.2016.04.077","volume":"26","author":"M Sang-Ngern","year":"2016","unstructured":"Sang-Ngern, M. et al. Withanolides derived from Physalis peruviana (Poha) with potential anti-inflammatory activity. Bioorg. Med. Chem. Lett. 26, 2755\u20132759 (2016).","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"84207_CR33","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1038\/ijo.2014.33","volume":"38","author":"T Takimoto","year":"2014","unstructured":"Takimoto, T. et al. 4\u03b2-hydroxywithanolide E isolated from Physalis pruinosa calyx decreases inflammatory responses by inhibiting the NF-\u03baB signaling in diabetic mouse adipose tissue. Int. J. Obes. (Lond) 38, 1432\u20131439 (2014).","journal-title":"Int. J. Obes. (Lond)"},{"key":"84207_CR34","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3390\/ijms18010023","volume":"18","author":"A Dasgupta","year":"2016","unstructured":"Dasgupta, A., Nomura, M., Shuck, R. & Yustein, J. Cancer\u2019s achilles\u2019 heel: Apoptosis and necroptosis to the rescue. Int. J. Mol. Sci. 18, 23 (2016).","journal-title":"Int. J. Mol. Sci."},{"key":"84207_CR35","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.bbrc.2007.02.030","volume":"355","author":"X Wang","year":"2007","unstructured":"Wang, X., Chen, W. & Lin, Y. Sensitization of TNF-induced cytotoxicity in lung cancer cells by concurrent suppression of the NF-\u03baB and Akt pathways. Biochem. Biophys. Res. Commun. 355, 807\u2013812 (2007).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"84207_CR36","doi-asserted-by":"publisher","first-page":"2687","DOI":"10.1128\/MCB.20.8.2687-2695.2000","volume":"20","author":"C Chen","year":"2000","unstructured":"Chen, C., Edelstein, L. C. & Gelinas, C. The Rel\/NF-\u03baB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol. Cell. Biol. 20, 2687\u20132695 (2000).","journal-title":"Mol. Cell. Biol."},{"key":"84207_CR37","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1146\/annurev-biochem-060815-014830","volume":"85","author":"K Newton","year":"2016","unstructured":"Newton, K. & Manning, G. Necroptosis and inflammation. Annu. Rev. Biochem. 85, 743\u2013763 (2016).","journal-title":"Annu. Rev. Biochem."},{"key":"84207_CR38","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1172\/JCI96148","volume":"128","author":"K Gong","year":"2018","unstructured":"Gong, K. et al. TNF-driven adaptive response mediates resistance to EGRF inhibition in lung cancer. J. Clin. Invest. 128, 2500\u20132518 (2018).","journal-title":"J. Clin. Invest."},{"key":"84207_CR39","doi-asserted-by":"crossref","unstructured":"Herrero Rivera, D. et al. Cardiovascular disease and survival in non-small cell lung cancer: A multicenter prospective assessment. Clin. Transl. Oncol. 21, 1220\u20131230 (2019).","DOI":"10.1007\/s12094-019-02047-5"},{"key":"84207_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1186\/1471-2407-13-158","volume":"13","author":"SH Jafri","year":"2013","unstructured":"Jafri, S. H., Shi, R. & Mills, G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): A retrospective review. BMC Cancer 13, 158 (2013).","journal-title":"BMC Cancer"},{"key":"84207_CR41","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.lungcan.2003.11.009","volume":"44","author":"F Guadagni","year":"2004","unstructured":"Guadagni, F. et al. Correlation between tumor necrosis factor-\u03b1 and D-dimer levels in non-small cell lung cancer patients. Lung Cancer 44, 303\u2013310 (2004).","journal-title":"Lung Cancer"},{"key":"84207_CR42","doi-asserted-by":"publisher","first-page":"5240","DOI":"10.1200\/JCO.2007.12.6953","volume":"25","author":"MS Tsao","year":"2007","unstructured":"Tsao, M. S. et al. Prognostic and predictive importance of p53 and RAS for adjuvant chemotherapy in non small-cell lung cancer. J. Clin. Oncol. 25, 5240\u20135247 (2007).","journal-title":"J. Clin. Oncol."},{"key":"84207_CR43","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.canlet.2014.12.003","volume":"357","author":"L Yang","year":"2015","unstructured":"Yang, L. et al. Mutations of p53 and KRAS activate NF-\u03baB to promote chemoresistance and tumorigenesis via dysregulation of cell cycle and suppression of apoptosis in lung cancer cells. Cancer Lett. 357, 520\u2013526 (2015).","journal-title":"Cancer Lett."},{"key":"84207_CR44","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1097\/JTO.0b013e31817c1b21","volume":"3","author":"S Regina","year":"2008","unstructured":"Regina, S. et al. Tissue factor expression in non-small cell lung cancer: Relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J. Thorac. Oncol. 3, 689\u2013697 (2008).","journal-title":"J. Thorac. Oncol."},{"key":"84207_CR45","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1634\/theoncologist.11-4-397","volume":"11","author":"R van Horssen","year":"2006","unstructured":"van Horssen, R., Ten Hagen, T. L. & Eggermont, A. M. TNF-\u03b1 in cancer treatment: Molecular insights, antitumor effects, and clinical utility. Oncologist 11, 397\u2013408 (2006).","journal-title":"Oncologist"},{"key":"84207_CR46","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.it.2016.06.002","volume":"37","author":"AT Ting","year":"2016","unstructured":"Ting, A. T. & Bertrand, M. J. M. More to life than NF-\u03baB in TNFR1 signaling. Trends Immunol. 37, 535\u2013545 (2016).","journal-title":"Trends Immunol."},{"key":"84207_CR47","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/nchembio.83","volume":"4","author":"A Degterev","year":"2008","unstructured":"Degterev, A. et al. Identification of RIP1 kinase as a specific cellular target of necrostatins. Nat. Chem. Biol. 4, 313\u2013321 (2008).","journal-title":"Nat. Chem. Biol."},{"key":"84207_CR48","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.smim.2014.05.004","volume":"26","author":"MS Hayden","year":"2014","unstructured":"Hayden, M. S. & Ghosh, S. Regulation of NF-\u03baB by TNF family cytokines. Semin. Immunol. 26, 253\u2013266 (2014).","journal-title":"Semin. Immunol."},{"key":"84207_CR49","doi-asserted-by":"publisher","first-page":"85","DOI":"10.3389\/fimmu.2019.00085","volume":"10","author":"M Mussbacher","year":"2019","unstructured":"Mussbacher, M. et al. Cell type-specific roles of NF-\u03baB linking inflammation and thrombosis. Front. Immunol. 10, 85 (2019).","journal-title":"Front. Immunol."},{"key":"84207_CR50","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.2741\/3782","volume":"16","author":"W Chen","year":"2011","unstructured":"Chen, W., Li, Z., Bai, L. & Lin, Y. NF-\u03baB in lung cancer, a carcinogenesis mediator and a prevention and therapy target. Front. Biosci. (Landmark Ed) 16, 1172\u20131185 (2011).","journal-title":"Front. Biosci. (Landmark Ed)"},{"key":"84207_CR51","doi-asserted-by":"publisher","first-page":"e0132496","DOI":"10.1371\/journal.pone.0132496","volume":"10","author":"G Malaponte","year":"2015","unstructured":"Malaponte, G. et al. Increased levels of NF-\u03baB-dependent markers in cancer-associated deep venous thrombosis. PLoS ONE 10, e0132496 (2015).","journal-title":"PLoS ONE"},{"key":"84207_CR52","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1002\/art.38182","volume":"65","author":"KA Campbell","year":"2013","unstructured":"Campbell, K. A. et al. Annexin A6 interacts with p65 and stimulates NF-\u03baB activity and catabolic events in articular chondrocytes. Arthritis Rheum. 65, 3120\u20133129 (2013).","journal-title":"Arthritis Rheum."},{"key":"84207_CR53","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1111\/j.1742-4658.2011.08132.x","volume":"278","author":"LX Deng","year":"2011","unstructured":"Deng, L. X. et al. The chromosomal protein HMGN2 mediates lipopolysaccharide-induced expression of \u03b2-defensins in A549 cells. FEBS J. 278, 2152\u20132166 (2011).","journal-title":"FEBS J."},{"key":"84207_CR54","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1126\/science.1062374","volume":"293","author":"L Chen","year":"2001","unstructured":"Chen, L., Fischle, W., Verdin, E. & Greene, W. C. Duration of nuclear NF-\u03baB action regulated by reversible acetylation. Science 293, 1653\u20131657 (2001).","journal-title":"Science"},{"key":"84207_CR55","doi-asserted-by":"publisher","first-page":"244","DOI":"10.3390\/ijms20020244","volume":"20","author":"KY Hsieh","year":"2019","unstructured":"Hsieh, K. Y., Wei, C. K. & Wu, C. C. YC-1 prevents tumor-associated tissue factor expression and procoagulant activity in hypoxic conditions by inhibiting p38\/NF-\u03baB signaling pathway. Int. J. Mol. Sci. 20, 244 (2019).","journal-title":"Int. J. Mol. Sci."},{"key":"84207_CR56","doi-asserted-by":"publisher","first-page":"7579","DOI":"10.3390\/ijms21207579","volume":"21","author":"JY Tsai","year":"2020","unstructured":"Tsai, J. Y., R\u00e9dei, D., Hohmann, J. & Wu, C. C. 12-Deoxyphorbol esters induce growth arrest and apoptosis in human lung cancer A549 cells via activation of PKC-\u03b4\/PKD\/ERK signaling pathway. Int. J. Mol. Sci. 21, 7579 (2020).","journal-title":"Int. J. Mol. Sci."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84207-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84207-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T23:18:54Z","timestamp":1670023134000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-021-84207-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,25]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["84207"],"URL":"https:\/\/doi.org\/10.1038\/s41598-021-84207-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,25]]},"assertion":[{"value":"10 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4610"}}